Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R C Hubbard

Showing results (31-40 of 56) with videos related to

Pageof 6
Sort By:
The Journal of Clinical Investigation|November 1, 1987
Oxidants spontaneously released by alveolar macrophages of cigarette smokers can inactivate the active site of alpha 1-antitrypsin, rendering it ineffective as an inhibitor of neutrophil elastaseR C Hubbard, F Ogushi, G A Fells, et al.
Chest|September 1, 1991
Use of a highly purified alpha 1-antitrypsin standard to establish ranges for the common normal and deficient alpha 1-antitrypsin phenotypesM L Brantly, J T Wittes, C F Vogelmeier, et al.
Anesthesia and Analgesia|August 29, 2001
The injectable cyclooxygenase-2-specific inhibitor parecoxib sodium has analgesic efficacy when administered preoperativelyP J Desjardins, E H Grossman, M E Kuss, et al.
The Journal of Clinical Investigation|February 1, 1991
Anti-neutrophil elastase defense of the normal human respiratory epithelial surface provided by the secretory leukoprotease inhibitorC Vogelmeier, R C Hubbard, G A Fells, et al.
Journal of Applied Physiology (Bethesda, Md. : 1985)|July 1, 1992
Intravenous recombinant secretory leukoprotease inhibitor augments antineutrophil elastase defenseP Birrer, N G McElvaney, A Gillissen, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 1, 1989
Fate of aerosolized recombinant DNA-produced alpha 1-antitrypsin: use of the epithelial surface of the lower respiratory tract to administer proteins of therapeutic importanceR C Hubbard, M A Casolaro, M Mitchell, et al.
Journal of Clinical Pharmacology|June 27, 2000
Celecoxib does not significantly alter the pharmacokinetics or hypoprothrombinemic effect of warfarin in healthy subjectsA Karim, D Tolbert, A Piergies, et al.
Journal of Clinical Pharmacology|October 5, 2001
A pharmacokinetic study of intramuscular (i.m.) parecoxib sodium in normal subjectsA Karim, A Laurent, M E Slater, et al.
The American Review of Respiratory Disease|February 1, 1988
Evaluation of the S-type of alpha-1-antitrypsin as an in vivo and in vitro inhibitor of neutrophil elastaseF Ogushi, R C Hubbard, G A Fells, et al.
The American Review of Respiratory Disease|November 1, 1991
Augmentation of functional prostaglandin E levels on the respiratory epithelial surface by aerosol administration of prostaglandin EZ Borok, A Gillissen, R Buhl, et al.
Pageof 6

Showing results (31-40 of 56) with videos related to

Sort By:
Pageof 6
The Journal of Clinical Investigation|November 1, 1987
Oxidants spontaneously released by alveolar macrophages of cigarette smokers can inactivate the active site of alpha 1-antitrypsin, rendering it ineffective as an inhibitor of neutrophil elastaseR C Hubbard, F Ogushi, G A Fells, et al.
Chest|September 1, 1991
Use of a highly purified alpha 1-antitrypsin standard to establish ranges for the common normal and deficient alpha 1-antitrypsin phenotypesM L Brantly, J T Wittes, C F Vogelmeier, et al.
Anesthesia and Analgesia|August 29, 2001
The injectable cyclooxygenase-2-specific inhibitor parecoxib sodium has analgesic efficacy when administered preoperativelyP J Desjardins, E H Grossman, M E Kuss, et al.
The Journal of Clinical Investigation|February 1, 1991
Anti-neutrophil elastase defense of the normal human respiratory epithelial surface provided by the secretory leukoprotease inhibitorC Vogelmeier, R C Hubbard, G A Fells, et al.
Journal of Applied Physiology (Bethesda, Md. : 1985)|July 1, 1992
Intravenous recombinant secretory leukoprotease inhibitor augments antineutrophil elastase defenseP Birrer, N G McElvaney, A Gillissen, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 1, 1989
Fate of aerosolized recombinant DNA-produced alpha 1-antitrypsin: use of the epithelial surface of the lower respiratory tract to administer proteins of therapeutic importanceR C Hubbard, M A Casolaro, M Mitchell, et al.
Journal of Clinical Pharmacology|June 27, 2000
Celecoxib does not significantly alter the pharmacokinetics or hypoprothrombinemic effect of warfarin in healthy subjectsA Karim, D Tolbert, A Piergies, et al.
Journal of Clinical Pharmacology|October 5, 2001
A pharmacokinetic study of intramuscular (i.m.) parecoxib sodium in normal subjectsA Karim, A Laurent, M E Slater, et al.
The American Review of Respiratory Disease|February 1, 1988
Evaluation of the S-type of alpha-1-antitrypsin as an in vivo and in vitro inhibitor of neutrophil elastaseF Ogushi, R C Hubbard, G A Fells, et al.
The American Review of Respiratory Disease|November 1, 1991
Augmentation of functional prostaglandin E levels on the respiratory epithelial surface by aerosol administration of prostaglandin EZ Borok, A Gillissen, R Buhl, et al.
Pageof 6